Nicholas Endres

Nick Endres is a Principal Scientist at Genentech with over 11 years of experience leading discovery-stage research in biochemical and cellular pharmacology. His team focuses on deciphering the pharmacological mechanisms of early lead compounds, with particular emphasis on KRAS-targeting agents and small molecule degraders. Notable contributions include supporting the development of GDC-6036 for KRAS G12C, uncovering novel inhibition mechanisms for KRAS G13D, and advancing degrader screening platforms that have delivered promising leads across multiple targets.

Before joining Genentech, Nick conducted postdoctoral research at UC Berkeley, where he pioneered single-cell microscopy assays to study EGFR activation. He earned his Ph.D. in Biophysics from UCSF, where he investigated the kinetics and motor function of kinesin proteins, and holds a B.S. in Physics from UC San Diego. Nick brings deep expertise in assay development, molecular pharmacology, and team leadership in early drug discovery.